(8r,9s) talazoparib

(8R,9S)-Talazoparib is Talazoparib enantiomer , less active than Talazoparib on the inhibition of PARP1 (IC50: 144 nM).

Talazoparib (LT-673) is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).

Talazoparib-[13C, D4] (Standard) is a reference standard of Talazoparib-[13C, D4] intended for quantitative analysis, quality control, and related biochemical research applications.

Talazoparib tosylate (BMN 673ts) is an orally active and highly potent PARP1/2 inhibitor with antitumor activity for the study of specific breast cancers.

(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is an orally active inhibitor of PARP1/2, with Ki values of 1.2 nM and 0.87 nM, respectively. It inhibits cellular PARylation at an EC50 of 2.51 nM. This compound leads to the accumulation of DNA damage and suppresses the proliferation of BRCA1/2-mutated MX-1 and Capan-1 cells, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib exhibits antitumor activity in mouse models.

Talazoparib-13C,D4 is a Talazoparib (T6253) compound labeled with 13C and deuterium. Talazoparib (T6253) is an orally active PARP1/2 inhibitor with Ki values of 1.2 nM for PARP1 and 0.87 nM for PARP2, demonstrating antitumor activity.